IOL Chemicals & Pharmaceuticals Reports Strong June 2026 Quarter

Revenue from operations for the quarter ended June 30, 2026, reached ₹756.26 Crore, a 37% increase from ₹551.69 Crore in the same period last year. Profit for the period more than doubled to ₹64.48 Crore from ₹33.96 Crore.

Reader Takeaway: Strong profit growth driven by pharma segment and international expansion.

What just happened

IOL Chemicals and Pharmaceuticals announced its financial results for the first quarter of fiscal year 2027 (ended June 30, 2026). The company reported a significant jump in both revenue and profit compared to the prior year's first quarter.

Why this matters

The strong performance indicates robust demand and successful execution by the company. The doubling of profit suggests improved operational efficiency or better product mix. The commencement of operations by its UK subsidiary signals international growth ambitions.

The backstory

In the quarter ended June 30, 2025, IOL Chemicals and Pharmaceuticals had reported revenues of ₹551.69 Crore and a profit of ₹33.96 Crore. The earnings per share (EPS) for the current quarter stands at ₹2.20, up from ₹1.16 in the corresponding period last year.

What changes now

The company's subsidiary, IOL Pharmaxis UK Limited, officially began business operations on April 2, 2026. This marks the first time this subsidiary's financials have been consolidated with the holding company's results.

Risks to watch

While the auditors provided an unmodified conclusion on the financial results, a minor subsidiary with assets of ₹0.12 crore was not reviewed by auditors. Management has stated this is not material to the group, but investors will monitor this.

Peer comparison

(Information not available in the provided text)

Context metrics (time-bound)

• Revenue from Operations: ₹756.26 Crore (June 30, 2026 quarter) vs ₹551.69 Crore (June 30, 2025 quarter).
• Profit for the period: ₹64.48 Crore (June 30, 2026 quarter) vs ₹33.96 Crore (June 30, 2025 quarter).
• Basic and Diluted EPS: ₹2.20 (June 30, 2026 quarter) vs ₹1.16 (June 30, 2025 quarter).

What to track next

Investors will be keen to observe the contribution of the new UK subsidiary to the company's overall performance in upcoming quarters. Continued growth in the pharmaceutical segment and overall margin improvement will also be key watch points.

Segment Performance Highlights:

• Pharmaceutical Segment: Revenue of ₹469.49 Crore and Profit Before Tax (PBT) and Interest of ₹68.81 Crore.
• Chemical Segment: Revenue of ₹364.96 Crore and PBT and Interest of ₹17.32 Crore.